Monument Health Rapid City Hospital
- Type
- Teaching hospital
- Where
- Rapid City, SD
- Medicare CCN
- 430077
- Received
- $661,810 in 115 records, 2023 ($128,008 general, $533,801 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: MONUMENT HEALTH RAPID CITY HOSPITAL Fuzzy (name and state)
- Federal award recipient: MONUMENT HEALTH RAPID CITY HOSPITAL, INC. Fuzzy (name and state)
- Nonprofit: MONUMENT HEALTH RAPID CITY HOSPITAL INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 63 | $128,008 |
| 2023 | Research payment | 52 | $533,801 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Amgen Inc. | 4 | $222,431 | 2023 |
| AstraZeneca UK Limited | 2 | $110,137 | 2023 |
| Intuitive Surgical, Inc. | 13 | $76,680 | 2023 |
| Eli Lilly and Company | 8 | $68,721 | 2023 |
| Esperion Therapeutics, Inc. | 4 | $46,025 | 2023 |
| Zimmer Biomet Holdings, Inc. | 2 | $25,312 | 2023 |
| American Regent | 2 | $20,263 | 2023 |
| Biosense Webster, Inc. | 6 | $19,000 | 2023 |
| Boston Scientific Corporation | 20 | $16,987 | 2023 |
| Genentech, Inc. | 2 | $11,516 | 2023 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $10,663 | 2023 |
| Linde Gas & Equipment Inc. | 22 | $7,260 | 2023 |
| AstraZeneca Pharmaceuticals LP | 4 | $5,000 | 2023 |
| AngioDynamics, Inc. | 1 | $4,800 | 2023 |
| JAZZ PHARMACEUTICALS INC. | 4 | $2,339 | 2023 |
| CSL Behring | 3 | $2,162 | 2023 |
| PFIZER INC. | 2 | $1,500 | 2023 |
| MicroVention, Inc. | 1 | $1,495 | 2023 |
| Tandem Diabetes Care, Inc. | 1 | $1,250 | 2023 |
| Insulet Corporation | 1 | $1,250 | 2023 |
| Merck Sharp & Dohme LLC | 1 | $1,000 | 2023 |
| Alnylam Pharmaceuticals Inc. | 1 | $1,000 | 2023 |
| E.R. Squibb & Sons, L.L.C. | 1 | $1,000 | 2023 |
| Olympus America Inc. | 1 | $1,000 | 2023 |
| Lilly USA, LLC | 1 | $1,000 | 2023 |
| Abbott Laboratories | 1 | $750 | 2023 |
| Novo Nordisk AS | 1 | $630 | 2023 |
| UROGEN PHARMA, INC. | 2 | $603 | 2023 |
| SCA Pharmaceuticals, LLC | 1 | $31 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 52 | $533,801 |
| Education | 14 | $77,930 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $20,000 |
| Space rental or facility fees (teaching hospital only) | 33 | $18,260 |
| Long term medical supply or device loan | 2 | $9,183 |
| Debt forgiveness | 1 | $1,000 |
| Grant | 3 | $1,000 |
| Gift | 2 | $603 |
| Food and Beverage | 1 | $31 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | AngioDynamics, Inc. | $4,800 | Long term medical supply or device loan | In-kind items and services | VenaCure 1470 Pro Device, ET | 2023 | |
| 2023-12-28 | Zimmer Biomet Holdings, Inc. | $22,248 | Research payment | Cash or cash equivalent | Persona Device, Knees | Persona Ti-Nidium Personalized Total Knee System | 2023 |
| 2023-12-04 | Eli Lilly and Company | $350 | Research payment | Cash or cash equivalent | A RANDOMIZED ACTIVE-CONTROLLED PARALLEL-GROUP PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2023 | |
| 2023-11-30 | MicroVention, Inc. | $1,495 | Research payment | Cash or cash equivalent | EVALUATION OF THE ROADSAVER STENT USED IN CONJUNCTION WITH THE NANOPARASOL EMBOLIC PROTECTION SYSTEM FOR CAROTID ARTERY | 2023 | |
| 2023-11-13 | Boston Scientific Corporation | $202 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-11-11 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-11-09 | Tandem Diabetes Care, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-11-07 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-10-31 | UROGEN PHARMA, INC. | $407 | Gift | In-kind items and services | JELMYTO Drug, UROTHELIAL CANCER | 2023 | |
| 2023-10-26 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-10-20 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-10-19 | Merck Sharp & Dohme LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-10-17 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-10-17 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-10-13 | Boston Scientific Corporation | $334 | Grant | In-kind items and services | Device, General - Therapies_EP | 2023 | |
| 2023-10-13 | Boston Scientific Corporation | $333 | Grant | In-kind items and services | Device, General - Therapies_EP | 2023 | |
| 2023-10-13 | Boston Scientific Corporation | $333 | Grant | In-kind items and services | Device, General - Therapies_EP | 2023 | |
| 2023-10-10 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-10-05 | PFIZER INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2023 | |
| 2023-10-02 | Boston Scientific Corporation | $1,100 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-10-02 | Boston Scientific Corporation | $215 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-09-21 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-08-29 | Alnylam Pharmaceuticals Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-08-28 | Eli Lilly and Company | $10,000 | Research payment | Cash or cash equivalent | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-08-10 | Intuitive Surgical, Inc. | $8,800 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-08-10 | Insulet Corporation | $1,250 | Education | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-08-09 | Esperion Therapeutics, Inc. | $31,687 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-08-08 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-08-08 | Boston Scientific Corporation | $61 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-08-05 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $30,000 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $8,800 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $8,200 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $8,200 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $5,300 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $3,000 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $1,200 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $900 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $850 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $600 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-28 | Intuitive Surgical, Inc. | $415 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-26 | Boston Scientific Corporation | $1,450 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX PERFORM | 2023 |
| 2023-07-25 | Boston Scientific Corporation | $4,383 | Long term medical supply or device loan | In-kind items and services | AVVIGO Guidance System Device, AVVIGO_IC | 2023 | |
| 2023-07-25 | Intuitive Surgical, Inc. | $415 | Education | In-kind items and services | DA VINCI SP Device, SURGERY | 2023 | |
| 2023-07-17 | Boston Scientific Corporation | $104 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-07-10 | Lilly USA, LLC | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-07-07 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-07-06 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-07-03 | Boston Scientific Corporation | $271 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-06-28 | Biosense Webster, Inc. | $5,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-12 | Boston Scientific Corporation | $456 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-05-26 | Novo Nordisk AS | $630 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4437 | 2023 |
| 2023-05-22 | SCA Pharmaceuticals, LLC | $31 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-05-19 | Esperion Therapeutics, Inc. | $13,563 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-05-15 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-05-15 | Boston Scientific Corporation | $969 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX PERFORM | 2023 |
| 2023-05-15 | Boston Scientific Corporation | $632 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-05-03 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-05-03 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-05-03 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-05-03 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-05-03 | UROGEN PHARMA, INC. | $196 | Gift | In-kind items and services | JELMYTO Drug, UROTHELIAL CANCER | 2023 | |
| 2023-04-27 | AstraZeneca Pharmaceuticals LP | $2,000 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2023 |
| 2023-04-27 | Eli Lilly and Company | $1,250 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-04-13 | Genentech, Inc. | $8,500 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2023 |
| 2023-04-12 | American Regent | $1,827 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2023 |
| 2023-04-12 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-04-07 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-04-07 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-04-07 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-04-07 | CSL Behring | $162 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-04-06 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-04-04 | Eli Lilly and Company | $1,380 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2023 | |
| 2023-04-04 | E.R. Squibb & Sons, L.L.C. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2023 | |
| 2023-03-24 | Amgen Inc. | $360 | Research payment | Cash or cash equivalent | P0 ASCVD Olpasiran Prescreening for CVOT | 2023 | |
| 2023-03-23 | Biosense Webster, Inc. | $5,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-23 | Biosense Webster, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-23 | Biosense Webster, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-23 | Biosense Webster, Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-23 | Biosense Webster, Inc. | $1,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,663 | Research payment | Cash or cash equivalent | Phase II dose finding PoCC in DKD | 2023 | |
| 2023-03-21 | JAZZ PHARMACEUTICALS INC. | $196 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2023 |
| 2023-03-16 | Zimmer Biomet Holdings, Inc. | $3,064 | Research payment | Cash or cash equivalent | Persona Device, Knees | Persona Ti-Nidium Personalized Total Knee System | 2023 |
| 2023-03-13 | Boston Scientific Corporation | $1,396 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-03-06 | Esperion Therapeutics, Inc. | $750 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-03-06 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-02-28 | Olympus America Inc. | $1,000 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-02-28 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-02-27 | Boston Scientific Corporation | $3,137 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX PERFORM | 2023 |
| 2023-02-27 | Boston Scientific Corporation | $228 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-02-23 | Amgen Inc. | $43,681 | Research payment | Cash or cash equivalent | Phase 3 - Cardiovascular Outcomes Trial | 2023 | |
| 2023-02-17 | Eli Lilly and Company | $30,853 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACE | 2023 | |
| 2023-02-14 | Eli Lilly and Company | $2 | Research payment | In-kind items and services | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACE | 2023 | |
| 2023-02-09 | JAZZ PHARMACEUTICALS INC. | $301 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2023 |
| 2023-02-09 | JAZZ PHARMACEUTICALS INC. | $52 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2023 |
| 2023-02-08 | Genentech, Inc. | $3,016 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | 2023 |
| 2023-02-03 | Eli Lilly and Company | $4,468 | Research payment | Cash or cash equivalent | A RANDOMIZED CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2023 | |
| 2023-01-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-01-30 | Eli Lilly and Company | $20,417 | Research payment | Cash or cash equivalent | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2023 | |
| 2023-01-25 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-01-24 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-01-21 | Amgen Inc. | $16,909 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2023 |
| 2023-01-19 | American Regent | $18,436 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2023 |
| 2023-01-19 | AstraZeneca UK Limited | $13,944 | Research payment | Cash or cash equivalent | A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolera | 2023 | |
| 2023-01-17 | Boston Scientific Corporation | $202 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-01-17 | Boston Scientific Corporation | $177 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-01-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-01-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-01-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-01-09 | Amgen Inc. | $161,481 | Research payment | In-kind items and services | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2023 |
| 2023-01-09 | AstraZeneca UK Limited | $96,193 | Research payment | Cash or cash equivalent | A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED | 2023 | |
| 2023-01-06 | JAZZ PHARMACEUTICALS INC. | $1,788 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2023 |
| 2023-01-05 | Abbott Laboratories | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FREESTYLE LIBRE 2 Device, Diabetes Care | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rapid City, SD, county Pennington County, SD, state South Dakota; placed by its city name.
| Measure | Place (city or town) Rapid City, SD | County Pennington County, SD | State South Dakota |
|---|---|---|---|
| Population B01003 | 77,946 | 113,512 | 907,428 |
| Population, 2020 census P1 | 74,703 | 109,222 | 886,667 |
| Median age B01002 | 39.1 | 40.1 | 38.0 |
| Under 18 B01001 | 22.0% | 22.0% | 24.2% |
| 65 and over B01001 | 20.7% | 20.1% | 18.0% |
| Households B11001 | 32,368 | 46,370 | 365,544 |
| Foreign born B05002 | 2.6% | 2.5% | 4.0% |
| Median household income B19013 | $70,870 | $74,517 | $75,081 |
| Median family income B19113 | $91,802 | $92,479 | $96,562 |
| Per capita income B19301 | $42,204 | $42,302 | $40,550 |
| Poverty rate B17001 | 12.5% | 11.2% | 11.9% |
| Unemployment rate B23025 | 2.6% | 3.2% | 2.9% |
| Civilian labor force B23025 | 39,452 | 57,369 | 475,223 |
| Mean commute (minutes) B08013 | 17.5 | 19.4 | 17.8 |
| Bachelor's degree or higher B15003 | 37.0% | 34.6% | 31.9% |
| Housing units B25001 | 35,577 | 51,681 | 408,584 |
| Owner-occupied B25003 | 62.9% | 69.3% | 68.6% |
| Renters B25003 | 37.1% | 30.7% | 31.4% |
| Median home value B25077 | $299,400 | $302,200 | $257,400 |
| Median gross rent B25064 | $1,109 | $1,120 | $946 |
| White, not Hispanic B03002 | 76.3% | 77.8% | 79.8% |
| Black B03002 | 1.2% | 1.1% | 2.1% |
| Hispanic or Latino B03002 | 6.1% | 5.7% | 4.8% |
| Asian B03002 | 1.3% | 1.2% | 1.4% |
| American Indian and Alaska Native B03002 | 7.1% | 6.0% | 7.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rapid City, SD.
Comments